On Monday, Eli Lilly And Co (NYSE:LLY) announced results from two Phase 3 studies of mirikizumab across two types of inflammatory bowel diseases (IBD). The studies showed patients treated with ...

Eli Lilly and Co. (NYSE:LLY) unveiled new data on Tuesday from LUCENT-3, the single-arm long-term Phase 3 open-label extension of LUCENT-1 and LUCENT-2, which evaluated the efficacy and safety of ...

At three years, over 80% of patients with moderately to severely active UC who were in remission with mirikizumab sustained long-term remission and relief from disruptive symptoms, including bowel ...

For decades, patients with inflammatory bowel disease have reported a familiar and frustrating pattern: periods of intense stress are often followed by worsening symptoms or full-blown disease flares.

Ease the symptoms of a UC flare, such as diarrhea, abdominal pain, and fever using expert-backed tips, and learn when to seek immediate medical attention.